Results

1–7 of 7 results for VIVID

Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2021
Impact of Delayed Treatment in Diabetic Retinal Disease: Experience From VISTA/VIVID and PANORAMA
Sunil Srivastava, MD
Annual Meeting Talks
2021
Incidence of New Diabetic Macular Edema in Fellow Eyes of Patients in the VISTA and VIVID Studies
Sumit Sharma, MD, FASRS
Annual Meeting Talks
2020
Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD, FASRS
Updates from the Field
2019
Sustained Diabetic Retinopathy Severity Improvement With Intravitreal Aflibercept in DME: Post Hoc Analysis of VISTA and VIVID
Rishi P. Singh, MD
Annual Meeting Talks
2019
Vision Threatening Complications in Patients With Diabetic Macular Edema: A Post Hoc Analysis of the VISTA and VIVID Trials
Diana V Do, MD, FASRS
Annual Meeting Talks
2019
Impact of Posterior Vitreous Detachment at Baseline on Treatment Outcomes For Diabetic Macular Edema in the VISTA and VIVID Trials
Ferhina S Ali, MD, MPH
On Demand Cases, Courses, and Papers
2017